INVESTORS

About Us

Founded in 1984, General Biologicals Corporation (GBC) is a pioneer in Taiwan’s in-vitro diagnostics (IVD) industry, originating from the National Hepatitis Prevention Program initiated by the Executive Yuan. For over 40 years, GBC has been committed to delivering innovative, accurate, and accessible diagnostic solutions that improve healthcare outcomes worldwide.

As a GMP-certified and ISO 13485-compliant manufacturer, GBC specializes in the research, development, production, and global distribution of advanced IVD products and integrated diagnostic technologies. Our solutions are trusted in 40+ countries, empowering hospitals, clinical laboratories, blood banks, and healthcare professionals with reliable, high-performance tools for disease detection and monitoring.

Core Expertise:

• Infectious & Respiratory Diseases
• Blood-Borne Viruses
• Fertility & Sexual Health
• Oncology & Tumor Markers
• Human Genetics
• Emerging Infectious Diseases

By leveraging protein-based and nucleic acid-based diagnostic platforms, GBC has built a fully integrated value chain — spanning R&D, manufacturing, clinical applications, and laboratory services — enabling breakthroughs in precision diagnostics.

Looking forward, GBC is extending beyond traditional IVD into next-generation healthcare solutions through its subsidiaries:

• CurieMed & Danner Lab — Digital medical diagnostics and clinical laboratory services
• GBP — P113 antimicrobial peptide (AMP) therapeutics and consumer healthcare innovations

With a strong global presence, cutting-edge technologies, and a mission to make world-class diagnostics and therapeutics accessible to all, GBC is transforming healthcare and empowering better lives.